Daewon Pharm (003220) — Cash Flow Quality Index
Daewon Pharm (003220) has a Cash Flow Quality Index of 2.25x as of December 2025. Operating cash flow of ₩30.61 Billion exceeds net income of ₩13.60 Billion, indicating high earnings quality where cash backs reported profits. Explore Daewon Pharm long-term investment allocation to see how much of total assets are deployed in long-term investments.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Daewon Pharm Cash Flow Quality Index (2011–2024)
Historical Cash Flow Quality Index for Daewon Pharm across 14 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check tangible net worth ratio of Daewon Pharm to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for Daewon Pharm (2011–2024)
Year-by-year earnings quality comparison for Daewon Pharm. For live market cap and the full company financial profile, see market value of Daewon Pharm.
| Year | Quality Index | Operating CF (KRW) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | 3.21x | ₩30.04 Billion | ₩9.35 Billion | ▲ +48.5% |
| 2023 | 2.16x | ₩51.73 Billion | ₩23.92 Billion | ▲ +103.1% |
| 2022 | 1.07x | ₩33.33 Billion | ₩31.28 Billion | ▼ -68.4% |
| 2021 | 3.37x | ₩22.41 Billion | ₩6.65 Billion | ▲ +151.3% |
| 2020 | 1.34x | ₩24.95 Billion | ₩18.62 Billion | ▲ +18.1% |
| 2019 | 1.13x | ₩30.97 Billion | ₩27.29 Billion | ▼ -32.7% |
| 2018 | 1.69x | ₩40.03 Billion | ₩23.74 Billion | ▲ +324.6% |
| 2017 | 0.40x | ₩4.27 Billion | ₩10.74 Billion | ▼ -61.3% |
| 2016 | 1.03x | ₩20.79 Billion | ₩20.24 Billion | ▼ -29.6% |
| 2015 | 1.46x | ₩25.82 Billion | ₩17.69 Billion | ▲ +31.5% |
| 2014 | 1.11x | ₩17.45 Billion | ₩15.73 Billion | ▲ +10.9% |
| 2013 | 1.00x | ₩12.32 Billion | ₩12.32 Billion | ▼ -30.5% |
| 2012 | 1.44x | ₩13.83 Billion | ₩9.61 Billion | ▼ -24.3% |
| 2011 | 1.90x | ₩17.93 Billion | ₩9.44 Billion | — |